Buyers are jockeying for a piece of the second-biggest U.S. corporate bond sale ever, painting a picture of insatiable demand for anything with a yield. Money flowing away from exchange-traded funds (ETFs) suggests something else.
Just as Actavis Plc marketed its $21 billion bond offering on Monday to help fund its acquisition of Botox maker Allergan Inc., investors yanked $519 million from BlackRock Inc.'s iShares Core U.S. Aggregate Bond ETF.
It was the biggest daily redemption in the fund's 11-year history, and brought outflows from U.S. ETFs focused on top-rated bonds to about $2 billion in the past week, according to data compiled by Bloomberg.
Complete your profile to continue reading and get FREE access to Treasury & Risk, part of your ALM digital membership.
Your access to unlimited Treasury & Risk content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical Treasury & Risk information including in-depth analysis of treasury and finance best practices, case studies with corporate innovators, informative newsletters, educational webcasts and videos, and resources from industry leaders.
- Exclusive discounts on ALM and Treasury & Risk events.
- Access to other award-winning ALM websites including PropertyCasualty360.com and Law.com.
*May exclude premium content
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
